BIO-CHEM(SH:603360)2021-04-23 16:00Financial Performance - Operating revenue for the first quarter reached CNY 218,397,085.71, a year-on-year increase of 9.37%[7] - Net profit attributable to shareholders decreased by 42.38% to CNY 51,831,316.56 compared to the same period last year[7] - Basic earnings per share fell by 41.18% to CNY 0.20[7] - The weighted average return on equity decreased by 3.11 percentage points to 5.27%[7] - Total operating revenue for Q1 2021 was CNY 218,397,085.71, an increase of 9.6% compared to CNY 199,682,629.30 in Q1 2020[30] - Gross profit for Q1 2021 was CNY 66,584,035.26, compared to CNY 99,569,350.15 in Q1 2020, indicating a decrease in profitability[30] - The net profit for Q1 2021 was CNY 51,831,316.56, representing a decrease of 42.4% from CNY 89,960,059.62 in Q1 2020[32] - The total profit for Q1 2021 was CNY 61,053,791.33, down from CNY 99,771,299.37 in Q1 2020, indicating a decline of 38.8%[31] Assets and Liabilities - Total assets increased by 6.32% to CNY 1,520,021,841.48 compared to the end of the previous year[7] - Total assets as of March 31, 2021, amounted to CNY 1,525,056,004.36, an increase from CNY 1,428,631,511.24 at the end of 2020[27] - Current liabilities totaled ¥480,516,093.42, an increase from ¥396,049,476.04 at the beginning of the period[22] - Total liabilities as of March 31, 2021, were CNY 478,988,620.94, compared to CNY 396,056,440.26 at the end of 2020, indicating increased leverage[27] - Total liabilities amounted to CNY 441,412,764.39, with non-current liabilities totaling CNY 45,363,288.35[43] - Owner's equity stood at CNY 988,283,192.35, with retained earnings of CNY 574,691,374.21[43] Cash Flow - Net cash flow from operating activities decreased by 41.40% to CNY 46,857,098.90[7] - The net cash flow from operating activities for Q1 2021 was CNY 46,857,098.90, a decrease of 41.5% from CNY 79,967,742.71 in Q1 2020[36] - The company experienced a net cash outflow from investing activities of ¥88,964,063.33 in Q1 2021, compared to a net outflow of ¥29,978,644.00 in Q1 2020, indicating a significant increase in investment expenditures[39] - Cash inflow from financing activities was ¥61,873,792.00 in Q1 2021, with a net cash flow from financing activities of ¥16,595,711.30, contrasting with a net outflow of ¥396,700.00 in Q1 2020[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,293[13] - The top two shareholders, Dalian Tongyun Investment Co., Ltd. and Dalian Sanxin Investment Co., Ltd., hold 29.00% and 28.00% of shares respectively[13] Research and Development - Research and development expenses surged by 287.55% to ¥6,142,918.54, reflecting significant expenditures on process improvements[16] - Research and development expenses for Q1 2021 were CNY 6,142,918.54, significantly higher than CNY 1,585,064.72 in Q1 2020, reflecting a focus on innovation[30] Operational Costs - Operating costs rose by 62.03% to ¥119,283,001.94, driven by rising raw material prices and the reclassification of certain expenses under new revenue recognition standards[16] - Total operating costs for Q1 2021 were CNY 151,813,050.45, up from CNY 100,113,279.15 in Q1 2020, representing a 51.5% increase[30] Inventory and Asset Management - Inventory levels decreased to CNY 73,251,196.52 from CNY 91,459,227.13 at the end of 2020, indicating improved inventory management[26] - The company reported a significant asset impairment loss of 21,485.33% due to a decline in product prices, resulting in inventory write-downs[16] Other Financial Metrics - Non-recurring gains and losses totaled CNY 1,095,802.21 for the period[10] - The company's trading financial assets decreased by 100% to 0 due to the maturity of structured deposits[15] - Accounts receivable financing decreased by 39.89% to ¥6,412,665.12, attributed to a reduction in receivable notes[15]